6.48  0.19 (3.02%)		06-18 16:00
Open: 6.45 High: 6.53 Volume: 471,611		Pre. Close: 6.29 Low: 6.3 Market Cap: 217(M)

Short term
Mid term
Targets	6-month :	8.09	1-year :	9.03
Resists	First :	6.92	Second :	7.73
Pivot price	6.28
Supports	First :	5.63	Second :	4.68
MAs	MA(5) :	6.21	MA(20) :	6.52
	MA(100) :	7.39	MA(250) :	6.57
MACD	MACD :	-0.3	Signal :	-0.3
%K %D	K(14,3) :	35.2	D(3) :	26.6
RSI	RSI(14): 48.6
52-week	High :	9.31	Low :	4.19

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ EPRX ] has closed below upper band by 36.0%. Bollinger Bands are 15% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	6.54 - 6.56	6.56 - 6.58
Low:	6.24 - 6.27	6.27 - 6.29
Close:	6.43 - 6.48	6.48 - 6.52

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology firm dedicated to the innovation, advancement, and commercialization of new technologies within the biotech sector. Its primary therapeutic focus revolves around a portfolio of product candidates, notably EP-104IAR, which is currently undergoing a Phase III clinical trial to address significant unmet medical needs, particularly offering pain relief for knee osteoarthritis. Another key candidate, EP-104GI, is progressing through Phase II trials for the treatment of eosinophilic esophagitis. Additionally, EP-104 is in preclinical development, exploring its potential for various inflammatory joint conditions, benign esophageal strictures, and applications via epidural delivery. Beyond these, the company is also developing drug candidates in the field of oncology. Originally established as Plaza Capital Partners Inc., the company rebranded to Eupraxia Pharmaceuticals Inc. in May 2012. Incorporated in 2011, Eupraxia Pharmaceuticals Inc. operates from its headquarters in Victoria, Canada.

Sat, 20 Jun 2026

Sat, 20 Jun 2026

Sat, 20 Jun 2026

Sat, 20 Jun 2026

Sat, 20 Jun 2026

Sat, 20 Jun 2026

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	65 (M)
Shares Float	50 (M)
Held by Insiders	14.2 (%)
Held by Institutions	41.9 (%)
Shares Short	3,560 (K)
Shares Short P.Month	3,080 (K)

EPS	-1.05
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.75
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-33.9 %
Return on Equity (ttm)	-54.6 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.73
Qtrly Earnings Growth	0 %
Operating Cash Flow	-33 (M)
Levered Free Cash Flow	-18 (M)

PE Ratio	-6.18
PEG Ratio	0
Price to Book value	3.7
Price to Sales	0
Price to Cash Flow	-12.95

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.